Joe Palca

Joe Palca is a science correspondent for NPR. Since joining NPR in 1992, Palca has covered a range of science topics — everything from biomedical research to astronomy. He is currently focused on the eponymous series, "Joe's Big Idea." Stories in the series explore the minds and motivations of scientists and inventors. Palca is also the founder of NPR Scicommers – A science communication collective.

Palca began his journalism career in television in 1982, working as a health producer for the CBS affiliate in Washington, DC. In 1986, he left television for a seven-year stint as a print journalist, first as the Washington news editor for Nature, and then as a senior correspondent for Science Magazine.

In October 2009, Palca took a six-month leave from NPR to become science writer in residence at The Huntington Library, Art Collections, and Botanical Gardens.

Palca has won numerous awards, including the National Academies Communications Award, the Science-in-Society Award of the National Association of Science Writers, the American Chemical Society's James T. Grady-James H. Stack Award for Interpreting Chemistry for the Public, the American Association for the Advancement of Science Journalism Prize, and the Victor Cohn Prize for Excellence in Medical Writing. In 2019, Palca was elected to the American Academy of Arts and Sciences for outstanding achievement in journalism.

With Flora Lichtman, Palca is the co-author of Annoying: The Science of What Bugs Us (Wiley, 2011).

He comes to journalism from a science background, having received a Ph.D. in psychology from the University of California at Santa Cruz, where he worked on human sleep physiology.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

Pfizer is ready to ask the Food and Drug Administration to authorize emergency use of the company's COVID-19 vaccine, after an updated analysis of the clinical trial data found the vaccine to be 95% effective.

A second COVID-19 vaccine now also appears highly effective in preventing illness following exposure to the virus that causes the disease.

The biotech company Moderna Inc. said Monday that its experimental vaccine was 94.5% effective in preventing disease, according to an analysis of its clinical trial.

The news comes a week after Pfizer and BioNTech said their vaccine was more than 90% effective.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

DAVID GREENE, HOST:

Updated at 3:15 p.m. ET

Pfizer's experimental COVID-19 vaccine appears to be working. The vaccine was found to be more than 90% effective, according to clinical results released by the company Monday.

That news comes from an interim analysis of a study involving 43,538 volunteers, 42% of whom had "diverse backgrounds."

Copyright 2020 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

Historically, tobacco plants are responsible for their share of illness and death. Now they may help control the COVID-19 pandemic.

Two biotech companies are using the tobacco plant, Nicotiana benthamiana, as bio-factories to produce a key protein from the coronavirus that can be used in a vaccine.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

RACHEL MARTIN, HOST:

Companies trying to make a vaccine for COVID-19 are trying a variety of approaches. Most involve laboratories capable of sophisticated biotechnology, but NPR's Joe Palca has this report about one approach for creating a vaccine which starts in a greenhouse.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

President Trump's medical team announced on Sunday that it had decided to treat the president with dexamethasone.

It was a decision that struck some doctors and COVID-19 specialists as surprising, given the fact that Dr. Sean Conley, the president's doctor, gave a fairly upbeat assessment of his patient's condition. Typically, only hospitalized COVID-19 patients in need of oxygen are given the drug.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

All right, now let's work through what treatments the president is getting and what they tell us with NPR science correspondent Joe Palca. Good morning, Joe.

JOE PALCA, BYLINE: Good morning.

White House physician Sean Conley says that President Trump was doing "very well" and that the symptoms he had are resolving and improving.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

SCOTT SIMON, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

SCOTT SIMON, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

SACHA PFEIFFER, HOST:

Updated at 7:00 a.m. ET

More than 100,000 people are taking part in studies to see if one or more COVID-19 vaccine candidates actually work.

Drugmaker AstraZeneca announced Saturday that its COVID-19 vaccine studies have resumed in the United Kingdom, though not yet in the United States. The vaccine trials had been placed on hold around the world earlier in the week after a U.K. participant in one of the studies developed a neurological illness.

Scientists and engineers in California are building a unique camera for a unique telescope.

The Rubin Observatory telescope going up on Cerro Pachón in north-central Chile can capture an unusually large swath of sky in a single image.

The camera capable of capturing those images has to be enormous. The one researchers are building at the SLAC National Accelerator Laboratory in Menlo Park, Calif., certainly is.

Several vaccines are currently in large-scale studies to see if they can prevent COVID-19, and more are on the way.

The primary goal of a COVID-19 vaccine is to keep people from getting very sick and dying. But there's another goal — to prevent the spread of the disease — and it's not clear most vaccine candidates currently under development can do that.

Some scientists think they can solve that problem by delivering a vaccine as a nasal spray.

Under normal circumstances, it could take years — if not decades — to bring a new vaccine to market. The COVID-19 pandemic has changed all that. In May, the Trump administration launched Operation Warp Speed with the goal of delivering initial doses of a safe and effective vaccine by January 2021 — shortening the development time from years to months.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

There are many approaches to making a vaccine against COVID-19. Some use genetic material from the coronavirus, some use synthetic proteins that mimic viral proteins and some use disabled versions of the virus itself.

But before any of these approaches can generate the antibodies to the coronavirus that scientists say are essential to protecting people from getting sick, the immune system has to be primed to make those antibodies.

That's the job of something called an adjuvant.

Nobody is eager to be stuck by a needle twice, so naturally many would view a COVID-19 vaccine that provides disease protection after a single injection as a good thing.

Two new studies released Thursday suggest that might be possible.

The COVID-19 vaccine candidate made by the U.S. biotech company Moderna and developed in collaboration with the National Institutes of Health starts its final phase of testing Monday.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

DAVID GREENE, HOST:

Pages